Delivery Order SPE2DR25D3306-SPE2DR26F5F0W
Award Date 12/2/25
Potential Completion Date 12/3/25
Potential Value $21K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $23,153.27 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on December 8, 2025, with completion scheduled for December 9, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor will perform this...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,931.68 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a delivery order valued at $7,181.62 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) with a firm fixed price and September 23, 2025 completion date. This is a competitively awarded, non-set-aside contract for pharmaceutical supply to support federal medical procurement needs. The award was issued to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's headquarters, which serves as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $36,535.91 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed price, non-set-aside contract represents a single delivery order fulfilling immediate pharmaceutical supply needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,228.39 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on November 6, 2025, with an ultimate completion date of November 7, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be performed at...
- The Defense Logistics Agency awarded a $8,996.88 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on December 11, 2025, with a completion deadline of December 12, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting...
- The Defense Logistics Agency has awarded AmerisourceBergen Drug Corp a delivery order valued at $6,223.32 for RINVOQ ER 30 mg tablets (30-count units) under a firm fixed price contract type. The award was issued on August 4, 2025, with an ultimate completion date of August 5, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a non-set-aside competitive award, reflecting AmerisourceBergen's capability to meet...
- The Defense Logistics Agency awarded a delivery order valued at $28.6K to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 14, 2025, with completion targeted for July 15, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. The award represents a continuation of AmerisourceBergen's substantial role as a pharmaceutical supplier to federal medical procurement, leveraging the company's existing indefinite delivery...
- The Defense Logistics Agency awarded a delivery order valued at $35.7K to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on December 2, 2025, with an ultimate completion date of December 3, 2025. This firm fixed-price, non-set-aside contract represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion vehicle running through December 2026 that serves as a comprehensive pharmaceutical support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for RINVOQ ER 45 mg tablets (28-count unit of use packaging) valued at $10,162.27 with a firm fixed-price structure. This is a competitive award with no set-aside designation and performance completion targeted for November 7, 2025. The award represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX,...